Registered title, quoted from ClinicalTrials.gov
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
An open trial on lymphoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 18 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 18
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteAffiliated Hospital of Qingdao University青岛大学附属医院QingdaoHospital page
- Study siteBeijing Tiantan Hospital首都医科大学附属北京天坛医院BeijingHospital page
- Study siteBeijing Tongren Hospital首都医科大学附属北京同仁医院BeijingHospital page
- Study siteFirst Affiliated Hospital of Bengbu Medical University蚌埠医学院第一附属医院BengbuHospital page
- Study siteFirst Affiliated Hospital of Nanchang University南昌大学第一附属医院NanchangHospital page
- Study siteFirst Affiliated Hospital, Zhejiang University浙江大学医学院附属第一医院HangzhouHospital page
- Study siteFirst Hospital of China Medical University中国医科大学附属第一医院ShenyangHospital page
- Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page
- Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
- Study siteHenan Provincial People's Hospital河南省人民医院ZhengzhouHospital page
- Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
- Study siteJiangxi Cancer Hospital江西省肿瘤医院NanchangHospital page
- Study siteSecond Affiliated Hospital of Xi'an Jiaotong University西安交通大学第二附属医院Xi'anHospital page
- Study siteSecond Hospital of Dalian Medical University大连医科大学附属第二医院DalianHospital page
- Study siteSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page
- Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
- Study siteWest China Hospital四川大学华西医院ChengduHospital page
- Study siteYantai Yuhuangding Hospital烟台毓璜顶医院YantaiHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06082102, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 4
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (4 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Prior systemic therapy including at least one anti-CD20 monoclonal antibody-containing regimen is required, with the following specifications:
Inclusion criterion 3
Administration of the specified anti-tumor therapies within 2 weeks prior to the first dose of the study treatment.
Exclusion criterion 1
Administration of any other investigational product within 4 weeks prior to the first dose of the study treatment, or concurrent participation in another clinical trial.(Excluding patients who have discontinued treatment and are in long-term follow-up).
Exclusion criterion 2
ECOG performance status (PS) score of 0-2.
Inclusion criterion 6
At least 1 measurable lesion confirmed through enhanced computed tomography (CT) or enhanced magnetic resonance imaging (MRI).
Inclusion criterion 5
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; other conditions the trial excludes; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06082102, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age ≥ 18 years , either sex.
- Histopathologically confirmed B-cell non-Hodgkin lymphoma MZL (splenic, nodal, or extra-nodal).
- Prior systemic therapy including at least one anti-CD20 monoclonal antibody-containing regimen is required, with the following specifications:
For combination therapies: Minimum of 2 completed treatment cycles For anti-CD20 monotherapy: Minimum of 4 administered doses Progression during treatment waives cycle/dose requirements
- Relapsed or refractory disease.
- At least 1 measurable lesion confirmed through enhanced computed tomography (CT) or enhanced magnetic resonance imaging (MRI).
- ECOG performance status (PS) score of 0-2.
Exclusion Criteria:
- Administration of the specified anti-tumor therapies within 2 weeks prior to the first dose of the study treatment.
- Administration of any other investigational product within 4 weeks prior to the first dose of the study treatment, or concurrent participation in another clinical trial.(Excluding patients who have discontinued treatment and are in long-term follow-up).
- Prior treatment with any types of BTK inhibitor.
- Patients refractory to lenalidomide plus rituximab (R2 regimen). Refractoriness is defined as either: Failure to achieve at least partial response (PR) after completing an adequate R2 treatment course (≥2 cycles at standard doses), OR Disease progression during R2 therapy or within 6 months after the last dose.
- Central nervous system (CNS) lymphoma, and lymphoma with CNS or meningeal involvements.
Quoted from ClinicalTrials.gov, NCT06082102, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06082102, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.